Bavarian Nordic: Publicly Traded And Its Impact

Bavarian Nordic is a publicly traded company that focuses on the research, development, and manufacturing of innovative life-saving vaccines. The company is a leading global supplier of travel vaccines with a range of products on the market, including vaccines for rabies, tick-borne encephalitis, typhoid, and cholera. The company's shares are traded on the Nasdaq Copenhagen exchange under the ticker symbol BAVA and on the OTC market under the ticker symbol BVNRY. As of August 2024, Bavarian Nordic had a market capitalisation of £2.19 billion, making it the 3631st most valuable company in the world.

Bavarian Nordic shares trade on Nasdaq Copenhagen under the ticker BAVA

Bavarian Nordic is a publicly traded company. Its shares trade on Nasdaq Copenhagen under the ticker BAVA. The company's shares are also available for US investors to trade on the OTC market under the ticker symbol BVNRY.

Nasdaq Copenhagen is part of Nasdaq Nordic, an equity market that brings together the trading and securities markets of Denmark, Sweden, Finland, Iceland, and the Baltic countries. It is owned by Nasdaq, Inc., a US-based multinational financial services and technology company.

The BAVA ticker symbol is used to identify Bavarian Nordic's shares on the Nasdaq Copenhagen exchange. This unique combination of letters is assigned by the exchange to facilitate trading and provide a simple way to track the company's stock performance.

The ticker symbol is often followed by a suffix that indicates the exchange on which the stock is traded. In this case, "CO" or "OMX" is used to represent Copenhagen. For example, you might see BAVA.CO or BAVA OMX: to denote that the stock is traded on the Copenhagen exchange.

The availability of Bavarian Nordic shares on the Nasdaq Copenhagen exchange under the ticker BAVA provides investors with a platform to trade the company's stock, facilitating liquidity and accessibility for those interested in investing in the company.

The company's IPO was in 1998

Bavarian Nordic is a publicly traded company. The company's IPO (initial public offering) was in 1998. Since then, the company has grown and expanded its operations, focusing on the research, development, and manufacturing of innovative life-saving vaccines.

Bavarian Nordic is a leading global supplier of travel vaccines, with a range of products on the market, including vaccines for rabies, tick-borne encephalitis, typhoid, and cholera. The company also supplies more than 70 countries with its smallpox/mpox vaccine, JYNNEOS®/IMVANEX®/IMVAMUNE®.

The company's shares are traded on the Nasdaq Copenhagen exchange under the ticker symbol BAVA. Additionally, an ADR program has been established, allowing US investors to trade Bavarian Nordic stock locally on the OTC market under the ticker symbol BVNRY.

As of September 2024, Bavarian Nordic had approximately 116,000 registered shareholders and 78,832,982 outstanding shares. The company's market capitalisation, or market cap, as of August 2024, was £2.19 billion, making it the 3631st most valuable company in the world by this metric.

Bavarian Nordic is committed to providing reliable and transparent information to its shareholders and the media about its business, development programs, and results. The company also offers an international working environment that prioritises job satisfaction and personal growth.

There are approximately 116,000 registered shareholders

Bavarian Nordic is a publicly traded company. The company's shares are traded on the Nasdaq Copenhagen exchange under the ticker symbol BAVA. An ADR program also allows US investors to trade Bavarian Nordic stock on the OTC market under the ticker symbol BVNRY.

Bavarian Nordic has approximately 116,000 registered shareholders as of September 2024. The company's shares are publicly traded, and anyone can purchase them through brokerage firms, including online brokerage services. However, it is important to note that Bavarian Nordic does not offer direct stock purchases from the company itself.

The company's market capitalization, or market cap, is the total market value of its outstanding shares. As of August 2024, Bavarian Nordic's market cap was reported to be £2.19 Billion, making it the 3631st most valuable company in the world by this metric. The company's shares outstanding were reported to be 78.1 million by MarketWatch in August 2016, while another source in September 2024 stated the number of outstanding shares as 78,832,982.

Bavarian Nordic's focus on vaccines and innovative life-saving treatments has attracted investors. The company is committed to providing reliable and transparent information to its shareholders and the media about its business, development programs, and results. The company's annual general meetings are held to present relevant information to shareholders, and the company also offers an international working environment with a focus on job satisfaction and personal growth.

The company has 78,832,982 outstanding shares

Bavarian Nordic is a publicly traded company. The company's shares are traded on the Nasdaq Copenhagen under the ticker symbol BAVA. An ADR program also allows US investors to trade the stock locally on the OTC market under the ticker symbol BVNRY.

Bavarian Nordic has 78,832,982 outstanding shares. This is a large number of shares, and it is important to note that each share carries one vote. The number of outstanding shares is used to calculate the company's market capitalization, which is the total market value of all the company's outstanding shares. As of August 2024, Bavarian Nordic's market capitalization was £2.19 billion, making it the 3631st most valuable company in the world by this metric.

The number of outstanding shares can be an important factor in a company's stock price and overall value. In general, a company with more outstanding shares will have a lower stock price, as the value of the company is spread across a larger number of shares. However, other factors, such as the company's earnings and growth rate, will also impact its stock price and market capitalization.

Bavarian Nordic's stock price has been influenced by various factors, including its focus on research and development, its commercial portfolio of vaccines, and its role as a supplier of vaccines to governments. For example, in 2022, the company's stock jumped after it reached a monkeypox vaccine deal with Canada and after the US ordered additional doses of the JYNNEOS vaccine.

In addition to its outstanding shares, Bavarian Nordic had approximately 116,000 registered shareholders as of September 2024. The company also has subsidiaries in the USA, Germany, and Switzerland, demonstrating its international presence.

The company has never paid dividends

Bavarian Nordic is a publicly traded company with shares traded on the Nasdaq Copenhagen under the ticker symbol BAVA. The company also has an ADR program that allows US investors to trade its stock locally on the OTC market under the ticker symbol BVNRY. While the company has a large number of shareholders and outstanding shares, it has never declared dividends.

The company's primary focus is on the research, development, and manufacturing of innovative life-saving vaccines, with a strong commitment to transparency in its business operations and results. With a market capitalization of approximately £2.19 billion as of August 2024, Bavarian Nordic is among the world's most valuable companies. The company's portfolio includes vaccines for rabies, tick-borne encephalitis, typhoid, cholera, Japanese encephalitis, hepatitis A, and smallpox/mpox.

Despite its success and market presence, Bavarian Nordic has never paid dividends to its shareholders. This decision could be attributed to the company's short-term and mid-to-long-term financial strategies. In the short term, the company intends to use its cash to pay significant milestones to GSK and Emergent BioSolutions, which are due in 2024 and 2025. By doing so, the company aims to fulfil its immediate financial obligations and maintain its relationships with these key partners.

In the mid-to-long term, Bavarian Nordic has different financial objectives. The company expects to increase its financial flexibility through a strong positive cash flow and improved access to debt financing. This strategy will enable the company to invest in growing its existing business, including its pipeline and selective acquisitions. By reinvesting cash into the business, Bavarian Nordic can drive growth, expand its operations, and potentially increase its market share. This approach demonstrates the company's commitment to creating long-term value for its shareholders, even without paying dividends.

By forgoing dividend payments, Bavarian Nordic can retain more of its profits and channel them back into the business. This strategy can fuel innovation, support research and development, and enhance the company's ability to adapt to changing market demands. It also enables the company to maintain a strong financial position, which can be advantageous when navigating economic downturns or unpredictable market conditions.

Frequently asked questions